Lobe Sciences Improves Balance Sheet

Executive Summary

• Lobe Sciences Ltd. will settle USD 137,130 (CAD 191,884.32) of related‑party liabilities by issuing 3,837,686 common shares at C$0.05 per share.
• The settlement converts debt to equity, strengthening the balance sheet and preserving cash for growth initiatives.
• Shares are subject to a four‑month statutory hold period and the transaction requires Canadian Securities Exchange approval; it is exempt from formal MI 61‑101 valuation and minority‑shareholder approval requirements.

Key Details

• Settlement Amount: USD 137,130 (CAD 191,884.32).
• Shares Issued: 3,837,686 common shares (“Settlement Shares”).
• Issue Price: C$0.05 per share.
• Creditor: Clearway Global, LLC – a related party holding >20% of Lobe’s common shares and controlled by a director/officer.
• Transaction Structure: Debt‑for‑equity conversion; no cash outflow required from Lobe.
• Hold Period: Statutory four‑month hold on Settlement Shares under Canadian securities laws and CSE policies.
• Regulatory Approval: Closing subject to approval by the Canadian Securities Exchange.
• Exemption Applied: Directors determined exemption from MI 61‑101 formal valuation and minority‑shareholder approval per sections 5.5(a) and 5.7(1)(a).
• Management Commentary: CEO Dr. Fred D. Sancilio stated the conversion “strengthens its balance sheet and aligns stakeholders with our long‑term growth strategy,” enhancing operational flexibility and potential stock liquidity.

Notable Quotes

"By converting liabilities into equity, Lobe strengthens its balance sheet and aligns stakeholders with our long‑term growth strategy," – Dr. Fred D. Sancilio, CEO & Chairman.
"This structure enhances operational flexibility, reflects our commitment to disciplined capital management, and may improve stock liquidity, particularly given the concentration of shares held by insiders and strategic partners." – Dr. Fred D. Sancilio